Ward L M, Konji V N, Ma J
Pediatric Bone Health Clinical and Research Programs, Children's Hospital of Eastern Ontario, Ottawa, ON, K1H 8L1, Canada.
Department of Pediatrics, University of Ottawa, Ottawa, ON, Canada.
Osteoporos Int. 2016 Jul;27(7):2147-2179. doi: 10.1007/s00198-016-3515-9. Epub 2016 Apr 28.
This article reviews the manifestations and risk factors associated with osteoporosis in childhood, the definition of osteoporosis and recommendations for monitoring and prevention. As well, this article discusses when a child should be considered a candidate for osteoporosis therapy, which agents should be prescribed, duration of therapy and side effects. There has been significant progress in our understanding of risk factors and the natural history of osteoporosis in children over the past number of years. This knowledge has fostered the development of logical approaches to the diagnosis, monitoring, and optimal timing of osteoporosis intervention in this setting. Current management strategies are predicated upon monitoring at-risk children to identify and then treat earlier rather than later signs of osteoporosis in those with limited potential for spontaneous recovery. On the other hand, trials addressing the prevention of the first-ever fracture are still needed for children who have both a high likelihood of developing fractures and less potential for recovery. This review focuses on the evidence that shapes the current approach to diagnosis, monitoring, and treatment of osteoporosis in childhood, with emphasis on the key pediatric-specific biological principles that are pivotal to the overall approach and on the main questions with which clinicians struggle on a daily basis. The scope of this article is to review the manifestations of and risk factors for primary and secondary osteoporosis in children, to discuss the definition of pediatric osteoporosis, and to summarize recommendations for monitoring and prevention of bone fragility. As well, this article reviews when a child is a candidate for osteoporosis therapy, which agents and doses should be prescribed, the duration of therapy, how the response to therapy is adjudicated, and the short- and long-term side effects. With this information, the bone health clinician will be poised to diagnose osteoporosis in children and to identify when children need osteoporosis therapy and the clinical outcomes that gauge efficacy and safety of treatment.
本文回顾了儿童骨质疏松症的表现、相关风险因素、骨质疏松症的定义以及监测和预防建议。此外,本文还讨论了儿童何时应被视为骨质疏松症治疗的候选对象、应开具何种药物、治疗持续时间以及副作用。在过去几年中,我们对儿童骨质疏松症的风险因素和自然病程的认识有了显著进展。这些知识促进了在这种情况下对骨质疏松症进行诊断、监测和最佳干预时机的合理方法的发展。当前的管理策略基于对高危儿童的监测,以识别并在那些自发恢复潜力有限的儿童中尽早治疗骨质疏松症的迹象。另一方面,对于骨折发生可能性高且恢复潜力小的儿童,仍需要进行预防首次骨折的试验。本综述重点关注形成当前儿童骨质疏松症诊断、监测和治疗方法的证据,强调对整体方法至关重要的关键儿科特异性生物学原理以及临床医生日常面临的主要问题。本文的范围是回顾儿童原发性和继发性骨质疏松症的表现和风险因素,讨论儿童骨质疏松症的定义,并总结监测和预防骨脆性的建议。此外,本文还回顾了儿童何时适合进行骨质疏松症治疗、应开具何种药物和剂量、治疗持续时间、如何判断治疗反应以及短期和长期副作用。有了这些信息,骨骼健康临床医生将能够诊断儿童骨质疏松症,并确定儿童何时需要骨质疏松症治疗以及衡量治疗疗效和安全性的临床结果。